ArticleThe Journal of antimicrobial chemotherapy2020
Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm.
Article in The Journal of antimicrobial chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 58 citations in OpenAlex.
- Bacterial-fungal interactions: connections and consequences.Essays in biochemistry · 2026Review
- Article
- Interactions betweenInfection and immunity · 2026Article
- Review
- Candida tropicalis culture supernatants modulate Pseudomonas aeruginosa antimicrobial resistance and biofilm formation.Scientific reports · 2025Article
- Combination effect of meropenem and antifungals againstJournal of medical microbiology · 2025Article
- Different aspects of Pseudomonas aeruginosa biofilm: an in-depth analysis from formation to detection.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- In vitro evaluation of tolerance ability of cross-kingdom biofilm towards oral dynamic fluctuations.BMC oral health · 2025Article
- Preventive Activity of an Arginine-Based Surfactant on the Formation of Mixed Biofilms of Fluconazole-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Who arrived first? Priority effects on Candida albicans and Pseudomonas aeruginosa dual biofilms.Communications biology · 2025Article
- Effect of Candida albicans' supernatant on biofilm formation and virulence factors of Pseudomonas aeruginosa through las/rhl System.BMC microbiology · 2025Article
- Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis.Mycopathologia · 2024Review
- Article
- Alteration of oral microbial biofilms by sweeteners.Biofilm · 2024Review
- Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis.Archives of microbiology · 2024Review
- Phage-antibiotic combinations to control Pseudomonas aeruginosa-Candida two-species biofilms.Scientific reports · 2024Article
- A gain-of-function mutation in zinc cluster transcription factor Rob1 drives Candida albicans adaptive growth in the cystic fibrosis lung environment.PLoS pathogens · 2024Article
- Surface adherence and vacuolar internalization of bacterial pathogens to the Candida spp. cells: Mechanism of persistence and propagation.Journal of advanced research · 2023Review
- Pseudomonas aeruginosa increases the susceptibility of Candida albicans to amphotericin B in dual-species biofilms.The Journal of antimicrobial chemotherapy · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPseudomonas aeruginosa is an opportunistic bacterium that infects the airways of cystic fibrosis patients, surfaces of surgical and burn wounds, and indwelling medical devices. Patients are prone to secondary fungal infections, with Candida albicans being commonly co-isolated with P. aeruginosa. Both P. aeruginosa and C. albicans are able to form extensive biofilms on the surfaces of mucosa and medical devices.
objectivesTo determine whether the presence of C. albicans enhances antibiotic tolerance of P. aeruginosa in a dual-species biofilm.
methodsSingle- and dual-species biofilms were established in microtitre plates and the survival of each species was measured following treatment with clinically relevant antibiotics. Scanning electron microscopy and confocal microscopy were used to visualize biofilm structure.
resultsC. albicans enhances P. aeruginosa biofilm tolerance to meropenem at the clinically relevant concentration of 5 mg/L. This effect is specific to biofilm cultures and is dependent upon C. albicans extracellular matrix polysaccharides, mannan and glucan, with C. albicans cells deficient in glycosylation structures not enhancing P. aeruginosa tolerance to meropenem.
conclusionsWe propose that fungal mannan and glucan secreted into the extracellular matrix of P. aeruginosa/C. albicans dual-species biofilms play a central role in enhancing P. aeruginosa tolerance to meropenem, which has direct implications for the treatment of coinfected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.